HTA Council Recommendation (as of 29 April 2025) The HTA Council recommends the government financing of Factor VIII Inhibitor bypassing activity powder solution for infusion (IV) for treatment of bleeding events for hemophilia B patients with inhibitors. (See below for more details) Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page
Factor VIII Inhibitor bypassing activity powder solution for infusion (IV) for treatment of bleeding events for hemophilia A patients with inhibitors
HTA Council Recommendation (as of 29 April 2025) The HTA Council recommends the government financing of Factor VIII Inhibitor bypassing activity powder solution for infusion (IV) for treatment of bleeding events for hemophilia A patients with inhibitors. (See below for more details) Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page
Plasma-derived Coagulation Factor VIII for treatment of bleeding in the pediatric population with hemophilia A
HTA Council Recommendation (as of 29 April 2025) The HTA Council recommends the government financing of Plasma-derived Coagulation Factor VIII for treatment of bleeding in the pediatric population with hemophilia A. (See below for more details) Relevant Information Evidence and Relevant Documents Assessment History Assessments Page
Plasma-derived Coagulation Factor VIII for prophylaxis/prevention of bleeding in the pediatric population with hemophilia A
HTA Council Recommendation (as of 29 April 2025) The HTA Council recommends the government financing of Plasma-derived Coagulation Factor VIII for prophylaxis/prevention of bleeding in the pediatric population with hemophilia A. (See below for more details) Relevant Information Evidence and Relevant Documents Assessment History Assessments Page